Sort
78,016 grants matching “breast cancer”
EFFECTIVE ORAL BENZIMIDAZOLE CARBAMATES FOR THE TREATMENT OF METASTATIC BREAST CANCER
$655,076Board Of Regents Of The University Of Nebraska · · FY2021 · Defense Health Agency
Acceptance and Commitment Therapy for Fear of Recurrence in Breast Cancer Survivors
$655,048Shelley A. Johns · Indiana University Indianapolis · R01 · FY2021 · CA
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.
$655,037Theresa A Guise · Indiana University Indianapolis · R01 · FY2016 · CA
Intervention of Pancreatic Oncogenic Pathways with Dietary Tocotrienol
$654,995Mokenge P. Malafa · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2008 · CA
Validation of Biomarkers of Risk for the Early Detection of Lung Cancer
$654,948Pierre P Massion · Vanderbilt University · U01 · FY2012 · CA
3D Photoacoustic Tomography (PAT)and Dynamic Contrast-Enhanced PAT Breast Imaging
$654,907Robert A Kruger · Optosonics, Inc. · R01 · FY2015 · CA
The Breast Cancer and the Workforce Communication App: A randomized controlled trial of an English/Spanish intervention to promote long-term job retention
$654,904Victoria S Blinder · Sloan-Kettering Inst Can Research · R37 · FY2019 · CA
Long-term Arm Morbidity Following Breast Cancer Treatment
$654,902Christine A. Miaskowski · University Of California, San Francisco · R01 · FY2010 · CA
Elucidating the molecular and contextual basis for IDLE ultralow risk lesions and the tumor immune microenvironment of high risk in situ and invasive breast cancers
$654,899Laura J Esserman · University Of California, San Francisco · U01 · FY2020 · CA
Development of selective Pin1 inhibitors to target a common oncogenic mechanism
$654,869Gerburg M Wulf · Beth Israel Deaconess Medical Center · R01 · FY2021 · CA
Development of selective Pin1 inhibitors to target a common oncogenic mechanism
$654,869Kun Ping Lu · Beth Israel Deaconess Medical Center · R01 · FY2018 · CA
Development of selective Pin1 inhibitors to target a common oncogenic mechanism
$654,869Gerburg M Wulf · Beth Israel Deaconess Medical Center · R01 · FY2020 · CA
Extending the Capabilities and Reach of EMERSE in Support of Cancer Research
$654,861David Alan Hanauer · University Of Michigan At Ann Arbor · U24 · FY2025 · CA
Georgia CaRes
$654,813Sharad A. Ghamande · Augusta University · UG1 · FY2014 · CA
Regulatory immune cells in immune suppression: The role of tBregs
$654,739Bira Arya · National Institute On Aging · ZIA · FY2016 · AG
Project 1: Clinical and immune impact of radiation and dual checkpoint blockade in patients
$654,726Robert H Vonderheide · University Of Pennsylvania · P01 · FY2018 · CA
Project 1: Clinical and immune impact of radiation and dual checkpoint blockade in patients
$654,726Robert H Vonderheide · University Of Pennsylvania · P01 · FY2017 · CA
Development of Non-Catalytic Peptide Inhibitors of Focal Adhesion Kinase (FAK) for Use in Melanoma
$654,706Timothy A Marlowe · Faknostics, Llc · R42 · FY2023 · CA
Efficacy of a Tobacco Quit Line for Childhood Cancer Survivors
$654,684Robert C Klesges · St. Jude Children'S Research Hospital · R01 · FY2010 · CA
Research Program
$654,644Alison Meredith Buttenheim · University Of Pennsylvania · P50 · FY2022 · CA
Unique targeting of PPARβ/δ regulation for cancer prevention and therapy
$654,596Jeffrey M Peters · Pennsylvania State University, The · R01 · FY2020 · CA
Unique targeting of PPARβ/δ regulation for cancer prevention and therapy
$654,594Jeffrey M Peters · Pennsylvania State University, The · R01 · FY2021 · CA
Environmental and Genetic Risk Factors For Breast Cancer: The Sister Study
$654,573Dale P Sandler · Environmental Health Sciences · Z01 · FY2007 · ES
Genetic Epidemiology of Cancer
$654,515Joan E. Bailey-Wilson · National Human Genome Research Institute · ZIA · FY2014 · HG
Population Modeling of Bladder Cancer Detection and Control
$654,490Thomas Trikalinos · Brown University · U01 · FY2022 · CA